Pinagbawalan ng Food and Drugs Administration (FDA) ang French drug manufacturer Sanofi Pasteur sa pagbenta ng kanilang produkto kasunod ng kontrobersiyal na dengue fever vaccine na Dengvaxia.
Sa pagdinig kanina ng Senate blue ribbon committee, sinabi ni FDA Director General Nela Charade Puno na hinahanda na nila ang administrative proceedings kasunod ng pagbuo task force para siyasatin ang pagbili ng P3.5-bilyon dengue vaccine sa Sanofi noong 2015.
“We have already, last Dec. 4, issued a suspension letter and advisory to Sanofi to withdraw the products in the market which include the distribution and selling of the Dengvaxia,” sabi ni Puno.
“We assure you that the FDA will not be sitting on this issue and that we will be taking and are already taking appropriate measures to protect the public.
In terms of the task force’s outputs and objectives, I would just like to highlight that we will be determining any and all administrative recourse moving forward. We will submit the findings of the committee as soon as the internal probe is concluded or as soon as the task force has completed all its facts and data gathering,” sambit pa nito.